Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 18/20 | 0.68 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.52 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30152477 | 0.85 | PDGFRB (0.64) | IRAK4MKNK1MKNK2PDGFRBPDGFRA | |
| SCHEMBL28839474 | 0.85 | PDGFRB (0.64) | IRAK4MKNK1MKNK2PDGFRBPDGFRA | |
| SCHEMBL30229311 | 0.85 | PDGFRB (0.64) | IRAK4MKNK1MKNK2PDGFRBPDGFRA | |
| SCHEMBL21106707 | 0.81 | IRAK4 (1.00) | IRAK4MKNK1MKNK2 | |
| SCHEMBL23924017 | 0.79 | PDGFRB (0.64) | IRAK4MKNK1MKNK2PDGFRBPDGFRA | |
| SCHEMBL29535684 | 0.79 | PDGFRB (0.64) | IRAK4MKNK1MKNK2PDGFRBPDGFRA | |
| Hydrochloric Acid SCHEMBL27894607 | 0.78 | PDGFRB (0.62) | IRAK4MKNK1MKNK2PDGFRBPDGFRA | |
| SCHEMBL20130876 | 0.77 | IRAK4 (0.73) | IRAK4 | |
| SCHEMBL18271551 | 0.77 | IRAK4 (0.66) | IRAK4 | |
| SCHEMBL30344129 | 0.77 | PARP1 (0.50) | MKNK1MKNK2PDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12202836-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-20230339960-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER (US) | 2023-10-26 | — | — | US | disclosed |
| US-11702424-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2023-07-18 | — | — | US | disclosed |
| CN-115715194-A | Methods of treating coronavirus disease 2019 | 辉瑞公司 | 2023-02-24 | — | — | CN | disclosed |
| EP-4125900-A1 | METHODS OF TREATING CORONAVIRUS DISEASE 2019 | Pfizer Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339960-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | TTR, TYR, ABL1 | IRAK4 1318/4885MKNK1 3874/4885MKNK2 3809/4885 |
| US-12202836-B2 | Bicyclic-fused heteroaryl or aryl compounds | TTR, TYR, ABL1 | IRAK4 1318/4885MKNK1 3874/4885MKNK2 3809/4885 |
| US-11702424-B2 | Bicyclic-fused heteroaryl or aryl compounds | UGT2B7, CYP3A43, CYP3A4 | IRAK4 4619/4885MKNK1 3924/4885MKNK2 3396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.